Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis

Tjokrowidjaja, A; Kok, PS; Antill, YC; Scott, CL; Mileshkin, LR; Friedlander, ML; Lee, CK

Author(s): Tjokrowidjaja, A; Kok, PS; Antill, YC; Scott, CL; Mileshkin, LR; Friedlander, ML; Lee, CK;
Journal Title: JNCI Cancer Spectrum
Abstract: BACKGROUND: Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma. METHODS: We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses. RESULTS: A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P = .20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P = .44; median PFS = 7.6 vs 9.5 months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P = .88; median overall survival = not reached vs 28.6 months). CONCLUSIONS: Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.
Publisher: Oxford Academic
Keywords: Humans; Female; *Endometrial Neoplasms/drug therapy/genetics/mortality; *DNA Mismatch Repair; *Randomized Controlled Trials as Topic; *Carboplatin/therapeutic use/administration & dosage; *Progression-Free Survival; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasm Recurrence, Local/drug therapy/genetics; Kaplan-Meier Estimate
Research Division(s): Cancer Biology And Stem Cells
PubMed ID: 39432670
Publisher's Version: https://doi.org/10.1093/jncics/pkae101
Open Access at Publisher's Site: https://doi.org/10.1093/jncics/pkae101
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-10-25 10:49:28

Last Modified: 2024-12-05 10:33:42